Investment Firms Raise Estimates for Complete Genomics, Danaher | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Two investment firms today separately raised estimates for Complete Genomics and Danaher.

Oppenheimer raised its share price target for Complete Genomics to $18.50, while Jefferies increased its 2011 EPS for Danaher to $2.70 and upped its share price target for the firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.